Harrow, Inc. (HROW)Healthcare | Drug Manufacturers - Specialty & Generic | Nashville, United States | NasdaqGM
41.81 USD
-0.67
(-1.577%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 40.98 -0.83 (-0.830%) ⇩ (July 13, 2026, 7:19 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:40 a.m. EDT
The investment case here is defined by a stark disconnect between the company's deteriorating operational reality and the market's speculative pricing. Fundamentally, the business is struggling hard: revenue is contracting by 7.6%, operating margins are deeply negative at nearly -50%, and the company is burning cash with no free cash flow to speak of. The balance sheet is fragile, carrying debt that is ten times its equity, which makes any further misstep dangerous. While the analyst consensus is aggressively bullish with a target price nearly double the current level, this appears to be a 'lottery ticket' thesis rather than a value play, given the lack of earnings power. However, the short-term outlook is buoyed by a powerful technical rebound. The stock has rallied significantly off its lows, breaking above key moving averages, and the recent price action shows strong relative strength compared to the broader market. This momentum is being amplified by heavy options speculation, with traders buying deep out-of-the-money calls hoping for a binary event to trigger a parabolic move. The statistical forecast models are weak and leaning slightly negative, which creates a tension: the fundamentals are terrible, but the technicals and speculative flow are currently driving the price up. For a trader, the momentum is the only play, but for an investor, the lack of profitability and high debt load makes holding risky until the company can demonstrate a path to sustainable earnings. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.081586 |
| MSTL | 0.108244 |
| AutoETS | 0.117959 |
| AutoARIMA | 0.117962 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 12.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.882 |
| Excess Kurtosis | 0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1060.52 |
| Revenue per Share | 7.24 |
| Market Cap | 1,558,472,320 |
| Forward P/E | 15.62 |
| Beta | 0.26 |
| Profit Margins | -5.57% |
| Previous Name | Harrow Health, Inc. |
| Website | https://www.harrow.com |
As of July 11, 2026, 3:40 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call volume is heavily skewed toward out-of-the-money strikes (OTM), suggesting a desire for explosive upside moves, while put volume concentrates near the money and slightly OTM, indicating a hedge against a drop to the $30-$40 range. The massive IV spike at deep OTM strikes ($29 calls, $15 puts) implies a binary event expectation, but the lack of consistent directional flow suggests uncertainty about whether the catalyst will result in a rally or a crash.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19258845 |
| Address1 | 1A Burton Hills Boulevard |
| Address2 | Suite 200 |
| All Time High | 140.0 |
| All Time Low | 0.5 |
| Ask | 53.67 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 743,350 |
| Average Daily Volume3 Month | 823,837 |
| Average Volume | 823,837 |
| Average Volume10Days | 743,350 |
| Beta | 0.255 |
| Bid | 30.15 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.77 |
| City | Nashville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 41.81 |
| Current Ratio | 2.476 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 42.44 |
| Day Low | 41.4 |
| Debt To Equity | 1,060.52 |
| Display Name | Harrow |
| Earnings Call Timestamp End | 1,778,587,200 |
| Earnings Call Timestamp Start | 1,778,587,200 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,392,000 |
| Earnings Timestamp Start | 1,786,392,000 |
| Ebitda | 38,866,000 |
| Ebitda Margins | 0.14466 |
| Enterprise To Ebitda | 45.356 |
| Enterprise To Revenue | 6.561 |
| Enterprise Value | 1,762,812,160 |
| Eps Current Year | 0.44333 |
| Eps Forward | 2.67667 |
| Eps Trailing Twelve Months | -0.37 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 37.7382 |
| Fifty Day Average Change | 4.0718 |
| Fifty Day Average Change Percent | 0.10789598 |
| Fifty Two Week Change Percent | 19.258844 |
| Fifty Two Week High | 54.85 |
| Fifty Two Week High Change | -13.039997 |
| Fifty Two Week High Change Percent | -0.23773925 |
| Fifty Two Week Low | 28.54 |
| Fifty Two Week Low Change | 13.27 |
| Fifty Two Week Low Change Percent | 0.46496147 |
| Fifty Two Week Range | 28.54 - 54.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,190,986,200,000 |
| Float Shares | 28,284,724 |
| Forward Eps | 2.67667 |
| Forward P E | 15.620155 |
| Free Cashflow | -5,045,750 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 373 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.74107003 |
| Gross Profits | 199,107,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15466 |
| Held Percent Institutions | 0.58877 |
| Implied Shares Outstanding | 37,275,107 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,360,281,600 |
| Last Split Factor | 1:5 |
| Long Business Summary | Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. |
| Long Name | Harrow, Inc. |
| Market | us_market |
| Market Cap | 1,558,472,320 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_21993612 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -14,961,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,558,472,223 |
| Number Of Analyst Opinions | 8 |
| Open | 42.09 |
| Operating Cashflow | 15,204,000 |
| Operating Margins | -0.49951 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 615 733 4730 |
| Post Market Change | -0.83000183 |
| Post Market Change Percent | -1.9851754 |
| Post Market Price | 40.98 |
| Post Market Time | 1,783,984,785 |
| Prev Name | Harrow Health, Inc. |
| Previous Close | 42.48 |
| Price Eps Current Year | 94.30898 |
| Price Hint | 2 |
| Price To Book | 54.298706 |
| Price To Sales Trailing12 Months | 5.8005853 |
| Profit Margins | -0.05568 |
| Quick Ratio | 2.157 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.669998 |
| Regular Market Change Percent | -1.57721 |
| Regular Market Day High | 42.44 |
| Regular Market Day Low | 41.4 |
| Regular Market Day Range | 41.4 - 42.44 |
| Regular Market Open | 42.09 |
| Regular Market Previous Close | 42.48 |
| Regular Market Price | 41.81 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 288,924 |
| Return On Assets | 0.03137 |
| Return On Equity | -0.35432997 |
| Revenue Growth | -0.076 |
| Revenue Per Share | 7.24 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 37,275,107 |
| Shares Percent Shares Out | 0.1918 |
| Shares Short | 7,148,618 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,688,674 |
| Short Name | Harrow, Inc. |
| Short Percent Of Float | 0.21350001 |
| Short Ratio | 8.52 |
| Source Interval | 15 |
| State | TN |
| Symbol | HROW |
| Target High Price | 88.0 |
| Target Low Price | 59.0 |
| Target Mean Price | 67.75 |
| Target Median Price | 61.5 |
| Total Cash | 95,973,000 |
| Total Cash Per Share | 2.575 |
| Total Debt | 300,668,000 |
| Total Revenue | 268,675,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 41.3409 |
| Two Hundred Day Average Change | 0.46910095 |
| Two Hundred Day Average Change Percent | 0.011347139 |
| Type Disp | Equity |
| Volume | 288,924 |
| Website | https://www.harrow.com |
| Zip | 37,215 |